A phase II trial was initiated with telaglenastat, a glutaminase inhibitor designed for tumors with mutations in the KEAP1/NRF2 pathway (NCT03872427), and another trial was initiated targeting stage IV non-small-cell lung cancer (NCT04265534); however, the latter was discontinued in 2022 after failing to demonstrate clinical benefit. Here, NFE2L2 is linked to non-small cell lung carcinoma.